- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.03. | H.C. Wainwright cuts OnKure Therapeutics price target to $34 | 1 | Investing.com | ||
| 10.03. | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 10.03. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 158 | GlobeNewswire (Europe) | - PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024... ► Artikel lesen | |
| 10.03. | OnKure Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.12.24 | OnKure reports positive early trial data for cancer drug OKI-219 | 1 | Investing.com | ||
| 10.12.24 | OnKure meldet positive frühe Studiendaten für Krebsmedikament OKI-219 | 3 | Investing.com Deutsch | ||
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.12.24 | OnKure Therapeutics, Inc.: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 | 104 | GlobeNewswire (Europe) | -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated... ► Artikel lesen | |
| 10.12.24 | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.12.24 | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 25.11.24 | OnKure Therapeutics, Inc.: OnKure Announces New Date for Upcoming Investor Call | 3 | GlobeNewswire (USA) | ||
| 07.11.24 | OnKure Therapeutics announces accounting firm change | 5 | Investing.com | ||
| 07.11.24 | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11.24 | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 01.11.24 | OnKure Therapeutics, Inc.: OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium | 2 | GlobeNewswire (USA) | ||
| 25.10.24 | vTv Therapeutics ends key license agreement with OnKure | 2 | Investing.com | ||
| 23.10.24 | OnKure files to sell 2.94M shares of Class A Common Stock for holders | 4 | Seeking Alpha | ||
| 10.10.24 | Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm | 1 | Benzinga.com | ||
| 10.10.24 | OnKure started at outperform by Oppenheimer, OKI-219 potential cited | 3 | Seeking Alpha | ||
| 10.10.24 | OnKure shares initiated with Outperform rating on drug potential | 3 | Investing.com |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,400 | +0,75 % | Pfizer Aktie: Branchendaten im Überblick | Pfizer bleibt ein zentraler Akteur für Anleger im Pharmasektor. Die aktuellen Entwicklungen unterstreichen die strategische Positionierung des Unternehmens inmitten globaler wirtschaftlicher Veränderungen... ► Artikel lesen | |
| SANOFI | 101,68 | -1,34 % | JPMORGAN stuft SANOFI auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi vor Zahlen zum ersten Quartal mit einem Kursziel von 110 Euro auf "Neutral" belassen. Diese dürften sich im Rahmen der... ► Artikel lesen | |
| INNOCAN PHARMA | 0,123 | -5,02 % | Breaking News: Großinvestor pumpt Cash in InnoCan Parma?! | ||
| ASSEMBLY BIOSCIENCES | 9,260 | -6,09 % | FY2029 Earnings Estimate for ASMB Issued By HC Wainwright | ||
| NEKTAR THERAPEUTICS | 0,634 | -10,96 % | Nektar Therapeutics files $300M mixed securities shelf | ||
| JAGUAR HEALTH | 4,850 | -9,51 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 24.03.2025 | The following instruments on XETRA do have their first trading 24.03.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 24.03.2025
Aktien
1 KYG93Y5D1039 VISEN Pharmaceuticals
2... ► Artikel lesen | |
| ROYALTY PHARMA | 28,380 | -2,10 % | UBS maintains neutral Royalty Pharma stock with $33 target | ||
| BRIDGEBIO PHARMA | 32,060 | -1,11 % | BridgeBio Pharma, Inc.: Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM | Acoramidis's hazard ratio of.41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved statistical significance in a pre-specified analysisThis... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 4,760 | -6,67 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled... ► Artikel lesen | |
| SOLIGENIX | 2,160 | -2,26 % | SOLIGENIX, INC. - 8-K, Current Report | ||
| KALA BIO | 5,270 | 0,00 % | KALA BIO GAAP EPS of -$1.74 | ||
| ACLARIS THERAPEUTICS | 1,410 | -4,31 % | Aclaris Therapeutics Aktie: Frische Impulse sorgen für Bewegung! | Die Aclaris Therapeutics Aktie verzeichnet derzeit eine bemerkenswerte Entwicklung am Markt. Nach einem monatlichen Rückgang von 11,98% hat sich der Kurs aktuell bei 1,69 EUR (Stand: 08. März 2025)... ► Artikel lesen | |
| NEUROGENE | 14,800 | +10,45 % | Neurogene (NASDAQ:NGNE) Issues Quarterly Earnings Results | ||
| ESSA PHARMA | 1,560 | 0,00 % | Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders | SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a pharmaceutical company... ► Artikel lesen | |
| LYRA THERAPEUTICS | 0,131 | -4,02 % | Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company continues to analyze data and explore opportunities... ► Artikel lesen |
Das Unternehmen ONKURE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 4,360 Euro und damit -2,90 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.
